Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study
Research Article | Jeremy S Abramson, Scott R Solomon, Jon E. Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim G.N.J. Mutsaers, Francisco J. Hernandez-Ilizaliturri, Koji...
Conclusions: Conclusions/Relevance: Liso-cel significantly improved EFS, CR rate, and PFS over chemotherapy ± ASCT as 2nd L treatment for large B-cell lymphoma. Liso-cel was well tolerated as 2nd L therapy with low rates of any grade and severe cytokine release syndrome and neurological events
Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36531004/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: We first introduce different formats, derivatives, and properties of chitosan. Next, given the barriers to therapeutic efficacy in solid tumors, we review advanced formulations of chitosan modules as efficient drug delivery systems to overcome tumor heterogeneity, multi-drug resistance, MRD, and metastasis. Finally, we discuss...
Diffuse large B-cell lymphoma: Early patient management | OTT
Most patients present with generalized lymphadenopathy. Extranodal involvement can be found in approximately 30% of the patients, most commonly affecting gastrointestinal tract, bones, testes, spleen, central nervous system (CNS), and...
Conclusions: The approach “agnostic” to specific molecular alterations of lymphoma cell includes antibody-drug conjugates (especially polatuzumab vedotin), immunotherapy comprising different antibodies with immunomodulatory effect (tafasitamab, lenalidomide), and T-cell engaging therapy (bispecific antibodies, early use of CAR T-cell). This...
Association of Minimal Residual Disease by a Single-Tube 8-Color Flow Cytometric Analysis With Clinical Outcome in Adult B-Cell Acute Lymphoblastic Leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36508349/
The single-tube 8-color MFC panel demonstrated a low cost, decent sensitivity, and comparability with polymerase chain reaction-MRD but an excellent performance in predicting RFS and OS, and thus could potentially...
Conclusions: "Conclusions: The single-tube 8-color MFC panel demonstrated a low cost, decent sensitivity, and comparability with polymerase chain reaction–MRD but an excellent performance in predicting RFS and OS, and thus could potentially be taken as a routine indicator in the evaluation of the treatment response for adult patients with...
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36507690/
Glofitamab therapy was effective for DLBCL. More than half the patients had an adverse event of grade 3 or 4. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT03075696.).
Conclusions: Glofitamab therapy was effective for DLBCL. More than half the patients had an adverse event of grade 3 or 4.